Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 250

1.

HER-2 amplification in tubular carcinoma of the breast.

Oakley GJ 3rd, Tubbs RR, Crowe J, Sebek B, Budd GT, Patrick RJ, Procop GW.

Am J Clin Pathol. 2006 Jul;126(1):55-8.

PMID:
16753605
3.

Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.

Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P.

Breast J. 2005 Jul-Aug;11(4):278-80.

PMID:
15982396
4.
5.

Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.

Bhargava R, Naeem R, Marconi S, Luszcz J, Garb J, Gasparini R, Otis CN.

Hum Pathol. 2001 Dec;32(12):1344-50.

PMID:
11774167
6.
7.
8.
9.
10.

Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.

Prati R, Apple SK, He J, Gornbein JA, Chang HR.

Breast J. 2005 Nov-Dec;11(6):433-9.

PMID:
16297088
11.

Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.

Van Calster B, Vanden Bempt I, Drijkoningen M, Pochet N, Cheng J, Van Huffel S, Hendrickx W, Decock J, Huang HJ, Leunen K, Amant F, Berteloot P, Paridaens R, Wildiers H, Van Limbergen E, Weltens C, Timmerman D, Van Gorp T, Smeets A, Van den Bogaert W, Vergote I, Christiaens MR, Neven P.

Breast Cancer Res Treat. 2009 Jan;113(1):181-7. doi: 10.1007/s10549-008-9914-7. Epub 2008 Feb 9.

PMID:
18264760
12.

Clinical findings and HER-2/neu gene amplification status of breast carcinoma patients.

Sahin FI, Yilmaz Z, Yagmurdur MC, Atac FB, Ozdemir BH, Karakayali H, Demirhan B, Haberal M.

Pathol Oncol Res. 2006;12(4):211-5. Epub 2006 Dec 25.

13.

Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.

Hussein MR, Abd-Elwahed SR, Abdulwahed AR.

Cell Biol Int. 2008 Jun;32(6):698-707. doi: 10.1016/j.cellbi.2008.01.007. Epub 2008 Jan 25.

PMID:
18296077
14.

Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.

Engelstaedter V, Schiffers J, Kahlert S, Mainka P, Engel J, Kirchner T, Diebold J, Mayr D.

Diagn Mol Pathol. 2012 Jun;21(2):77-83. doi: 10.1097/PDM.0b013e31823b6e43.

PMID:
22555090
16.

p185 overexpression in 220 samples of breast cancer undergoing primary surgery: comparison with c-erbB-2 gene amplification.

Dalifard I, Daver A, Goussard J, Lorimier G, Gosse-Brun S, Lortholary A, Larra F.

Int J Mol Med. 1998 May;1(5):855-61.

PMID:
9852307
17.

Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use.

Bánkfalvi A, Simon R, Brandt B, Bürger H, Vollmer I, Dockhorn-Dworniczak B, Lellé RJ, Boecker W.

Histopathology. 2000 Nov;37(5):411-9.

PMID:
11119122
18.

Assessment of Her-2/neu gene amplification status in breast carcinoma with equivocal 2+ Her-2/neu immunostaining.

Mostafa NA, Eissa SS, Belal DM, Shoman SH.

J Egypt Natl Canc Inst. 2011 Mar;23(1):41-6. doi: 10.1016/j.jnci.2011.07.006. Epub 2011 Sep 8.

19.
20.

Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.

D'Andrea MR, Limiti MR, Bari M, Zambenedetti P, Montagutti A, Ricci F, Pappagallo GL, Sartori D, Vinante O, Mingazzini PL.

Breast Cancer Res Treat. 2007 Mar;101(3):279-84. Epub 2006 Jul 12.

PMID:
16835704

Supplemental Content

Support Center